Alnylam Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 05/19/2024
Alnylam Pharmaceuticals Inc Stock Forecast and Price Target
In recent months, seven notable analysts have provided yearlong price targets for Alnylam Pharmaceuticals Inc, with the average target coming in at $217.50. If it were to be achieved, this would result in a potential upside of approximately 45.58 percent from the most recent closing price in May, 2024. The high end is $400.00, and the low is $138.00. Although you may not be interested in ALNY stock, you should still be aware of its competitors.
45.58% Upside
Alnylam Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Alnylam Pharmaceuticals Inc's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $159.70 – an increase of 100.00%. Over the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$770.00 | $636.99 | 13.96% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$154.64 | $174.55 | 9.93% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$131.19 | $130.51 | 9.00% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.64 | $32.87 | 6.49% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$445.21 | $457.59 | 2.70% |
Alnylam Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Alnylam Pharmaceuticals Inc's Revenue has grown from $492.85M to $1.83B – a 270.96% increase. Next year, analysts are expecting Revenue to reach $2.16B – an increase of 18.32%. Over the next seven years, the forecast is for Revenue to grow by 429.53%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$982.29 | $961.26 | 6.89% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.03 | $58.15 | 22.64% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$174.06 | $220.47 | 24.67% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Hold |
17
|
$35.25 | $44.86 | 24.82% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$10.98 | $11.73 | 9.29% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$274.26 | $284.08 | 9.39% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.37 | $49.29 | 14.68% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$59.53 | $87.92 | 57.90% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$37.31 | $55.60 | 60.81% |
Alnylam Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030
Alnylam Pharmaceuticals Inc's EBITDA has decreased by 71.26% In the last three years, from $-793.67M to $-228.12M. In the following year, the 7 analysts surveyed believe that Alnylam Pharmaceuticals Inc's EBITDA will decrease by 164.33%, reaching $146.74M. According to professionals, by 2030, Alnylam Pharmaceuticals Inc's EBITDA will have decreased by 2000.10%, falling down to $4.33B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$155.83 | $145.00 | 5.88% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$220.06 | $315.92 | 75.41% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$29.83 | $44.75 | 34.09% |
Alnylam Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Alnylam Pharmaceuticals Inc's EBIT has decreased from $-828.44M to $-282.18M – a 65.94% drop! In the next year, analysts believe that EBIT will reach $-447.34M – an increase of 58.53%. In 2030, professionals predict that Alnylam Pharmaceuticals Inc's EBIT will decrease by 2025.01%, reaching $5.43B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$13.54 | $37.00 | 25.55% |
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$28.09 | $35.67 | 42.40% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£13.37 | £28.89 | 131.34% |
Alnylam Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Alnylam Pharmaceuticals Inc's EPS has grown from $-6.38 to $0.00 – a 100.00% increase. Next year, analysts are expecting EPS to reach $-3.26 – an increase of 100.00%. Over the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$16.48 | $29.44 | 109.34% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$43.48 | $69.00 | 42.59% |
| CPRX Stock Forecast | Catalyst Pharmaceuticals | Buy |
16
|
$16.49 | $26.20 | 57.67% |